PD-L1 upregulation by lytic induction of Epstein-Barr Virus - ScienceDirect

Epstein‒Barr virus–associated cellular immunotherapy - Cytotherapy

The RNA polymerase III–RIG-I axis in antiviral immunity and inflammation: Trends in Immunology

Epstein–Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy - American Journal of Transplantation

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease: Molecular Therapy - Oncolytics

Herpes simplex virus and HIV-1: deciphering viral synergy - The Lancet Infectious Diseases

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease: Molecular Therapy - Oncolytics

Frontiers Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update

PD-L1 upregulation by lytic induction of Epstein-Barr Virus - ScienceDirect

RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells - ScienceDirect

Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers - Modern Pathology

RSV Downregulates IL-21/IL-21R On TFH Cells VIA PD-L1 Induction in APCS Impairing Protective Humoral Responses

RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells - ScienceDirect